February 26, 2020 05:50 AM ESTUpdated 08:23 AM

Takeda swoops in to buy little biotech partner and its celiac drug poised to 'change standard of care'

Amber Tong

Senior Editor

Having spent three years carefully grooming PvP Biologics and its drug for celiac disease, Takeda is happy enough with the proof-of-concept data to buy it all.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Takeda swoops in to buy little biotech partner and its celiac drug poised to 'change standard of care'

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

GSK accuses Pfizer and BioNTech of mRNA patent infringement

Bristol Myers outlines ‘about 12’ pipeline cuts as it executes major cutbacks

Updated: Bristol Myers plans $1.5B in cost cuts, including 2,200 jobs, as CEO promises more ‘agile’ company

Drug and biotech companies join lobbying push on China bill as scrutiny of WuXi continues

Sage focuses on successful launch of postpartum depression drug

Despite oncology cutbacks, Sanofi isn’t out of the game yet with early assets

Take­da swoops in to buy lit­tle biotech part­ner and its celi­ac drug poised to 'change stan­dard of care'

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

more like this

GSK ac­cus­es Pfiz­er and BioN­Tech of mR­NA patent in­fringe­ment

Bris­tol My­ers out­lines ‘about 12’ pipeline cuts as it ex­e­cutes ma­jor cut­backs

Up­dat­ed: Bris­tol My­ers plans $1.5B in cost cuts, in­clud­ing 2,200 jobs, as CEO promis­es more ‘ag­ile’ com­pa­ny

Drug and biotech com­pa­nies join lob­by­ing push on Chi­na bill as scruti­ny of WuXi con­tin­ues

Sage fo­cus­es on suc­cess­ful launch of post­par­tum de­pres­sion drug

De­spite on­col­o­gy cut­backs, Sanofi isn’t out of the game yet with ear­ly as­sets

Takeda swoops in to buy little biotech partner and its celiac drug poised to 'change standard of care'

GSK accuses Pfizer and BioNTech of mRNA patent infringement

Bristol Myers outlines ‘about 12’ pipeline cuts as it executes major cutbacks

Updated: Bristol Myers plans $1.5B in cost cuts, including 2,200 jobs, as CEO promises more ‘agile’ company

Drug and biotech companies join lobbying push on China bill as scrutiny of WuXi continues

Sage focuses on successful launch of postpartum depression drug

Despite oncology cutbacks, Sanofi isn’t out of the game yet with early assets